Business Standard

Lupin's New Jersey facility gets 13 US FDA observations

The observations do not, however, imply any restriction on supplies

Lupin, Boehringer Ingelheim ink $700-mn deal for anti-cancer drug
Premium

Sohini Das Mumbai
Mumbai-based drug major Lupin said that it's New Jersey facility has received thirteen observations from the US drug regulator. The facility accounts for less than  5 percent Lupin's global turnover. 

The observations do not, however, imply any restriction on supplies. 

"U.S. FDA inspection of the Company's Somerset, New Jersey (USA) facility. The U.S. FDA has concluded an inspection at the Company's wholly owned subsidiary Novel Laboratories, Inc., based in Somerset, NJ. The inspection commenced on March 7, 2022 and concluded on March 30, 2022. The inspection closed with thirteen observations," Lupin said. 
 
The company further added that it is confident
Topics : Lupin USFDA

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Mar 31 2022 | 8:31 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com